Advertisement

Topics

Immune Pharmaceuticals, Inc. Company Profile

18:17 EDT 22nd June 2018 | BioPortfolio

Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead program, bertilimumab, is a first-in-class, fully human monoclonal antibody that targets and lowers levels of eotaxin-1, a chemokine that plays a role in immune responses and attracts eosinophils to the site of inflammation. By neutralizing eotaxin-1, bertilimumab may prevent the migration of eosinophils and other cells, thus helping to relieve associated inflammatory conditions. Currently, we are conducting two phase 2 clinical trials to test bertilimumab in patients suffering from bullous pemphigoid and ulcerative colitis, respectively. Bertilimumab may have application in other diseases, including NASH, atopic dermatitis, immune and inflammatory hepatitis, and asthma.


News Articles [1167 Associated News Articles listed on BioPortfolio]

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2018

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / February 6, 2018 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic a...

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals to Present at the Biotech Showcase Annual Conference on January 10, 2018

ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / January 4, 2018 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic an...

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals Announces Adjournment of Annual Meeting

Annual Meeting to Resume Thursday, February 15, 2018 ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / January 26, 2018 / Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel ...

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals Announces Acceptance of Late-Breaking Abstract at the American Academy of Dermatology Annual Meeting 2018

Oral Presentation to Include Positive Interim Results from Its Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid ENGLEWOOD CLIFFS, NJ / ACCESSWIRE / January 10, 2018 / Immune Pharmaceutic...

Immune Pharmaceuticals Inc.: Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update

- 5 of 6 Proposals Pass with Shareholder Approval - Meeting Adjourned Solely with Respect to Proposal 4 - Ratification of the Reverse Stock Split - Company Outlines Key Corporate and Clinical Mile...

The right drug, to the right patient, at the right price

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is developing precision immunotherapies for inflammatory diseases and cancer. Immune’s core programme includes Bertilimumab (currently in phase II in ulcer...

Immune Pharmaceuticals And Bertilimumab: A Work In Progress

Takeda pens immuno-oncology deal with Noile-Immune Biotech

Takeda Pharmaceutical Co. Ltd., through its Takeda Oncology/Millennium Pharmaceuticals Inc. division, marks its entrance into the chimeric antigen receptor T-cell (CART) therapy space through a develo...

Drugs and Medications [294 Associated Drugs and Medications listed on BioPortfolio]

Yervoy [E.R. Squibb & Sons, L.L.C.]

These highlights do not include all the information needed to use YERVOY safely and effectively. See full prescribing information for YERVOY. YERVOY (ipilimumab)Injection, for intravenous infusionInit...

Nabi-hb [Biotest Pharmaceuticals Corporation]

Hepatitis B Immune Globulin (Human) Nabi-HB Solvent Detergent Treated and Filtered

Nabi-hb [Biotest Pharmaceuticals Corporation]

Hepatitis B Immune Globulin (Human) Nabi-HB Solvent Detergent Treated and Filtered

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

PubMed Articles [1699 Associated PubMed Articles listed on BioPortfolio]

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?

Familial hypercholesterolemia is characterized by high LDL cholesterol and an elevated risk to develop coronary heart disease. Mutations in LDL receptor-mediated cholesterol uptake are the main cause ...

Post-production handling and administration of protein pharmaceuticals and potential instability issues.

The safety and efficacy of protein pharmaceuticals depend not only on biological activity, but also on purity levels. Impurities may be process related due to limitations in manufacturing, or product ...

A General Strategy for Site-Selective Incorporation of Deuterium and Tritium into Pyridines, Diazines and Pharmaceuticals.

Methods to incorporate deuterium and tritium atoms into organic molecules are valuable for medicinal chemistry. The prevalence of pyridines and diazines in pharmaceuticals means that new ways to label...

Environmental concentrations of pharmaceuticals directly affect phytoplankton and effects propagate through trophic interactions.

Pharmaceuticals are found in freshwater ecosystems where even low concentrations in the range of ng Lmay affect aquatic organisms. In the current study, we investigated the effects of chronic exposure...

Clinical Trials [2990 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1753 Associated Companies listed on BioPortfolio]

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patien...

Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) is dedicated to alleviating the burden of patients suffering from autoimmune diseases by developing novel immunotherapeutic agents. Immun...

Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Our lead program, bertilimuma...

Novis Pharmaceuticals

Novis Pharmaceuticals is a leading national distributor of some of the world's leading plasma-derived products such as albumin, immune globulin, hyperimmunes and anti-hemophilic Factors VII, VIII ...

Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvan...

More Information about "Immune Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Immune Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Immune Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Immune Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immune Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Immune Pharmaceuticals, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...


Corporate Database Quicklinks



Searches Linking to this Company Record